Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia

Mutair, Abbas Al; Shamou, Jinan; Alhumaid, Saad; Layqah, Laila; Ahmad, Gasmelseed Y.; Koritala, Thoyaja; Mohaini, Mohammed Al; Almahmoud, Sana; Barry, Mazin; Khan, Amjad; Dhama, Kuldeep; Al-Jamea, Lamiaa H.; Woodman, Alxeander; Rabaan, Ali A.

doi:10.1016/j.jiph.2022.01.013

Cited by 7 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many antiviral drugs and monoclonal antibodies were authorized for COVID-19 in persons who are more prone to get severely ill. The efficacy of favipiravir against several viral infections has emerged as possible therapy for COVID-19 [29]. The pharmacokinetic profile of favipiravir is quite complex [30].…”

Section: Discussionmentioning

confidence: 99%

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation

2023

View full text Add to dashboard Cite

Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release tablets. In vitro dissolution testing was investigated for favipiravir tablets in three different pH media. The pharmacokinetic features of favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter “AUC0-t” vs. percent dissolved was used to develop level C in vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro release results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmax of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. Level C IVIVC was developed successfully. It was concluded that Egyptian volunteers had comparable Pk values to American and Caucasian volunteers, however they were considerably different from Japanese subjects. AUC0-t vs. % dissolved was used to develop level C IVIVC to set the optimum dissolution medium. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.

show abstract

Section: Discussionmentioning

confidence: 99%

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation

2023

View full text Add to dashboard Cite

show abstract

“…Many antiviral drugs and monoclonal antibodies were authorized for COVID-19 in persons who are more prone to get severely ill. The e cacy of favipiravir against several viral infections has emerged as possible therapy for COVID-19 [29]. The pharmacokinetic pro le of favipiravir is quite complex [30].…”

Section: Discussionmentioning

confidence: 99%

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy EgyptianVolunteers and Development of Level C In-vitro In-vivo Correlation

Bendas

Rezk

Badr³

2022

Preprint

View full text Add to dashboard Cite

Background and Objective Favipiravir is an antiviral drug used to treat influenza. It is also being investigated for the treatment of a variety of other viral diseases, including SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic (Pk) features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release (IR) tablets.Methods In vitro dissolution testing was investigated for favipiravir tablet, Avigan® 200 mg tablets, in three different pH media. The pharmacokinetic (Pk) features of favipiravir were examined in healthy male Egyptian volunteers. A newly developed and validated LC-MS/MS method was used to analyze real plasma samples of the healthy volunteers. Level C in vitro in vivo correlation (IVIVC) was developed to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets.Results In vitro dissolution results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cp max of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. AUC0-t vs. % dissolved was used to develop level C IVIVC for favipiravir (IR) tablets.Conclusions When compared to American and Caucasian volunteers, Egyptian participants had comparable Pk values, however they were considerably different from Japanese subjects. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.

show abstract

“…However, a few studies [ 18 , 25 , 26 ] specifically indicated that the therapeutic dose did not lower the overall number of arterial or venous thrombosis deaths. Additional studies [ 25 , 27 , 28 ] focused on COVID-19 patients in Riyadh and examined various anticoagulant regimens. For example, a study [ 21 ] conducted in Barcelona found that the therapeutic dose of enoxaparin, 1.5 mg/kg/24 hours or 1 mg/kg/12 hours for patients whose creatinine clearance [CrCl] > 30 mL/min, and 1 mg/kg/24 hours for patients whose CrCl < 30 mL/min, looks like to be associated with a higher risk of bleeding among critically ill COVID-19 patients without a corresponding decrease in VTE events and mortality in the ICU.…”

Section: Introductionmentioning

confidence: 99%

Anticoagulation dosage strategy therapy, length of stay, and all-cause mortality in critically ill COVID-19 patients admitted to the intensive care unit

Vennu,

Alshammary

2024

Medicine

View full text Add to dashboard Cite

Few studies examined several anticoagulation (AC) dosage strategy therapies for various outcomes among coronavirus disease-2019 (COVID-19) patients. However, this AC dosage strategy therapy has not been investigated to assess the length of stay (LOS) and all-cause mortality among critically ill COVID-19 patients admitted to the intensive care unit (ICU), especially in the eastern province of Saudi Arabia. Thus, this study aimed to examine the association of AC dosage strategy therapy with the LOS and all-cause mortality among critically ill COVID-19 patients admitted to the ICU. We enrolled 170 patients aged 18 years or older, had a confirmed COVID-19, and were hospitalized in a tertiary care facility in the eastern province of Saudi Arabia between March 1, 2020, and January 31, 2021. Patients (n = 56) who received Enoxaparin at a dose of less than or equal to 5000 units of unfractionated heparin thrice daily were categorized as receiving a “prophylaxis” dose. Patients (n = 114) who received a therapeutic dose but not a prophylaxis dose were categorized as receiving a “therapeutic dose.” The 30-day ICU LOS was the main outcome, while all-cause mortality was the secondary outcome. The covariate-adjusted logistic regression analysis revealed that the therapeutic dose was significantly associated with a 1.74-fold longer ICU LOS and 6.60-fold greater mortality risk than the prophylaxis dose. Critically ill COVID-19 patients who received the therapeutic dose had a longer ICU LOS and higher mortality than those who received the prophylaxis dose.

show abstract

Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia

Cited by 7 publications

References 55 publications

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy EgyptianVolunteers and Development of Level C In-vitro In-vivo Correlation

Anticoagulation dosage strategy therapy, length of stay, and all-cause mortality in critically ill COVID-19 patients admitted to the intensive care unit

Contact Info

Product

Resources

About